Zobrazeno 1 - 10
of 214
pro vyhledávání: '"M. Spino"'
Autor:
A. Sanluis-Verdes, P. Colomer-Vidal, F. Rodriguez-Ventura, M. Bello-Villarino, M. Spinola-Amilibia, E. Ruiz-Lopez, R. Illanes-Vicioso, P. Castroviejo, R. Aiese Cigliano, M. Montoya, P. Falabella, C. Pesquera, L. Gonzalez-Legarreta, E. Arias-Palomo, M. Solà, T. Torroba, C. F. Arias, F. Bertocchini
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
The crucial first step in the biodegradation of polyethylene plastic is oxidation of the polymer. This has traditionally required abiotic pre-treatment, but now Bertocchini and colleagues report two wax worm enzymes capable of catalyzing this oxidati
Externí odkaz:
https://doaj.org/article/1e4cdebc5139427db98ba85be4fd1b34
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Joel M. Schrock, Gavril W. Pasternak, Christina M. Spino, Stacy M. Stabler, Charles G. Longen, Felix J. Kim, Jacqueline C. Marino
Publikováno v:
Molecular pharmacology. 84(5)
The Sigma1 receptor (Sigma1) is an endoplasmic reticulum (ER) integral membrane protein that is highly expressed in a number of cancer cell lines. Small molecule compounds targeting Sigma1 (Sigma1 ligands) inhibit cancer cell proliferation and induce
Autor:
Amid Khan, Eric Gnall, MaryAnn C. Wertan, Marwan Badri, Francis P. Sutter, Timothy Shapiro, Paul Coady, Christina M. Spino, Frank C. McGeehin
Publikováno v:
Journal of the American College of Cardiology. 67:112
Multiple options for the treatment of multivessel disease now exist including hybrid revascularization. Nuances in hybrid revascularization need further evaluation including timing of these procedures and optimal antiplatelet therapy. We retrospectiv
Publikováno v:
Biochemical and biophysical research communications. 426(2)
Treatment with sigma1 receptor (Sigma1) ligands can inhibit cell proliferation in vitro and tumor growth in vivo. However, the cellular pathways engaged in response to Sigma1 ligand treatment that contribute to these outcomes remain largely undefined
Publikováno v:
Medical Hypotheses. 51:489-491
Several clinical studies demonstrate reduced serum concentrations of renally excreted drugs in patients with cystic fibrosis (CF). To explain this phenomenon, we propose a model supporting increased proximal tubular secretion of certain drugs in indi
Publikováno v:
Mutagenesis. 18(5)
Measurements of chromosomal aberrations were made in 10 thalassaemia major patients treated long-term with deferiprone (at least 5 years) and compared with an equal number of patients matched for age, sex and iron overload, treated long-term with def
Autor:
I. Agache, I. Annesi-Maesano, A. Bonertz, F. Branca, A. Cant, Z. Fras, F. Ingenrieth, L. Namazova-Baranova, M. Odemyr, A. Spanevello, S. Vieths, A. Yorgancioglu, M. Alvaro-Lozano, D. Barber Hernandez, T. Chivato, S. Del Giacco, Z. Diamant, I. Eguiluz-Gracia, R. G. van Wijk, P. Gevaert, A. Graessel, P. Hellings, K. Hoffmann-Sommergruber, M. Jutel, S. Lau, A. Lauerma, J. Maria Olaguibel, L. O’Mahony, C. Ozdemir, O. Palomares, O. Pfaar, J. Sastre, G. Scadding, C. Schmidt-Weber, P. Schmid-Grendelmeier, M. Shamji, I. Skypala, M. Spinola, O. Spranger, M. Torres, A. Vereda, S. Bonini
Publikováno v:
Педиатрическая фармакология, Vol 16, Iss 5, Pp 281-295 (2020)
The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision‐makers in the field of allergy,
Externí odkaz:
https://doaj.org/article/b15666add1f64a81aa5f0201b863f2e3
Publikováno v:
Pharmaceutical research. 13(6)
For the assessment of bioequivalence it is assumed that drug clearance in each subject on each of the study days is the same and any observed differences in AUC and/or Cmax between a brand and generic formulation are due to differences in bioavailabi